A5032756521- Multiple Myeloma Research and Treatments
- Single-cell and spatial transcriptomics
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Chemokine receptors and signaling
- Cell Image Analysis Techniques
- Chronic Lymphocytic Leukemia Research
- Liver Diseases and Immunity
- Mast cells and histamine
- RNA modifications and cancer
- CRISPR and Genetic Engineering
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Material Properties and Applications
- Cancer Mechanisms and Therapy
- Digital Imaging for Blood Diseases
- Immune Cell Function and Interaction
- 14-3-3 protein interactions
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chemical Synthesis and Analysis
- Advanced Theoretical and Applied Studies in Material Sciences and Geometry
Institute for Molecular Medicine Finland
2020-2024
University of Helsinki
2020-2024
Skolkovo Institute of Science and Technology
2020-2021
Multiple myeloma (MM) is characterized by extensive immunoglobulin production leading to an excessive load on protein homeostasis in tumor cells. Aminopeptidases contribute proteolysis catalyzing the hydrolysis of amino acids from proteins or peptides and function downstream ubiquitin–proteasome pathway. Notably, aminopeptidases can be utilized delivery antibody peptide-conjugated drugs, such as melflufen, currently clinical trials. We analyzed expression 39 aminopeptidase genes MM samples...
Machine learning and single-cell data inform personalized drug combinations that selectively co-inhibit cancer cell populations.
Abstract Liver fibrosis (LF) is a dangerous clinical condition with no available treatment. Inflammation plays critical role in LF progression. Glucocorticoid-induced leucine zipper (GILZ, encoded mice by the Tsc22d3 gene) mimics many of anti-inflammatory effects glucocorticoids, but its has not been directly addressed. Here, we found that GILZ deficiency was associated elevated CCL2 production and pro-inflammatory leukocyte infiltration at early stage, resulting enhanced development. RNA...
Ribosome biogenesis is among the founding processes in cell. During first stages of ribosome biogenesis, polycistronic precursor ribosomal RNA passes complex multistage maturation after transcription. Quality control preribosomal (pre-rRNA) processing precisely regulated by non-ribosomal proteins and structural features pre-rRNA molecules, including modified nucleotides. However, many participants rRNA are still unknown or poorly characterized. We report that m6A methyltransferase Mettl3...
Introduction : Design of objects complex forms (non-linear, round, dynamic in their geometry) currently causes difficulties the construction geometry and documentation various project stages. In this paper, proven approaches towards modeling are presented. Here, authors mean that represent planes bent three directions, which shall be built according to rules graphical display drawings. Methods A toolkit Autodesk Revit software (Masses, Model In-Place) is considered together with an...
The bone marrow microenvironment interacts with malignant cells and regulates cancer survival immune evasion in multiple myeloma (MM). We investigated the profiles of longitudinal samples from patients newly diagnosed MM (n = 18) using cytometry by time-of-flight. results before during treatment were compared between good (GR, n 11) bad (BR, 7) responses to lenalidomide/bortezomib/dexamethasone-based treatment. Before treatment, GR group had a lower tumor cell burden higher number T...
Abstract Characterizing the heterogeneity in human leukemias is critical for understanding mechanisms of disease onset, uncovering biomarkers diagnosis, and guiding research into novel treatment approaches. While extensive focus has been placed on characterizing molecular leukemia by modern omics technologies, comparatively less emphasis studying diversity holistic morphological changes that occur single cells context disease. Here, we report a approach to different hematological...
Abstract Multiple myeloma represents a complex hematological malignancy, characterized by its wide array of genetic and clinical events. The introduction proteasome inhibitors, such as carfilzomib or bortezomib, into the therapeutic landscape has notably enhanced quality life survival rates for patients suffering from this disease. Nonetheless, significant obstacle in long-term efficacy treatment is inevitable development resistance to PIs, posing substantial challenge managing disease...
Background Patients with relapsed/refractory multiple myeloma (RRMM) and high-risk genetic abnormalities such as del(17p) TP53 mutation have poor response to standard therapies shorter survival compared patients without these aberrations. Here, we investigated the activity mechanism of action peptide-drug conjugate melphalan flufenamide (melflufen) in wild type (TP53wt) mutant (TP53mut) models assessed efficacy melflufen and/or mutation. Methods We evaluated ex vivo 24 bone marrow (BM)...
Abstract Intratumoral cellular heterogeneity necessitates multi-targeting therapies for improved clinical benefits in patients with advanced malignancies. However, systematic identification of patient-specific treatments that selectively co-inhibit cancerous cell populations poses a combinatorial challenge, since the number possible drug-dose combinations vastly exceeds what could be tested scarce patient cells. Here, we developed scTherapy, machine learning model leverages single-cell...
Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: The novel peptide-drug conjugate melphalan flufenamide (melflufen) was recently approved by the EMA for treatment of relapsed/refractory multiple myeloma (MM). Considering low overall survival these patients challenges to decide their treatment, information that can support selection predict outcome is urgently needed. Aims: We aimed identify potential indicators melflufen response in MM as...
Abstract The extensive primary and secondary drug resistance in acute myeloid leukemia (AML) requires rational approaches to design personalized combinatorial treatments that exploit patient-specific therapeutic vulnerabilities optimally target disease-driving AML cell subpopulations. However, the large number of AML-relevant combinations makes testing impossible scarce patient cells. This problem is further exacerbated by translational challenge how such selective do not only show...
Background: Immunoglobulin light-chain amyloidosis (AL) is a rare disease caused by plasma cell secretion of misfolded light chains that assemble as amyloid fibrils, which deposit on vital organs causing organ dysfunction. Similar to AL, multiple myeloma (MM) also atypical (PC) expansion in the bone marrow. Although, much research has been done MM understand mechanisms and develop effective treatments, knowledge related AL still limited. Notably, there little information available regarding...